Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 292-298

  Garcia Albeniz, Xabier ^a,b   Nan, Hongmei ^b,c   Valeri, Linda ^a   Morikawa, Teppei ^d   Kuchiba, Aya ^a,d   Phipps, Amanda I ^e   Hutter, Carolyn M ^e   Peters, Ulrike ^e   Newcomb, Polly A ^e   Fuchs, Charles S ^b,d   Giovannucci, Edward L ^a,b   Ogino, Shuji ^a,b,d   Chan, Andrew T ^b,f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD7 PROTEIN; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CALCIUM INTAKE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE INACTIVATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN METHYLATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL;

ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SMAD7 PROTEIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84873542162     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs335     Document Type: Article

References (38)

1. Tenesa,A. et al. (2010) Ten common genetic variants associated with colorectal cancer risk are not associated with survival after diagnosis. Clin. Cancer Res., 16, 3754-3759.
2. Houlston,R.S. et al. (2010) Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat. Genet., 42, 973-977.
3. Houlston,R.S. et al. (2008) Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat. Genet., 40, 1426-1435.
4. Tomlinson,I.P. et al. (2008) A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet., 40, 623-630.
5. Tomlinson,I.P. et al. (2011) Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet., 7, e1002105.
6. Kocarnik,J.D. et al. (2010) Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis. Cancer Epidemiol. Biomarkers Prev., 19, 3131-3139.
7. Hutter,C.M. et al. (2010) Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis. BMC Cancer, 10, 670.
8. Dunlop,M.G. et al. (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat. Genet., 44, 770-776.
9. Peters,U. et al. (2012) Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum. Genet., 131, 217-234.
10. Phipps,A.I. et al. (2012) Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. Gastroenterology, 143, 51-4.e4.
11. Stampfer,M.J. et al. (1984) Test of the National Death Index. Am. J. Epidemiol., 119, 837-839.
12. Pai,J.K. et al. (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N. Engl. J. Med., 351, 2599-2610.
13. Morikawa,T. et al. (2011) Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA, 305, 1685-1694.
14. Ogino,S. et al. (2007) Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J. Mol. Diagn., 9, 305-314.
15. Ogino,S. et al. (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut, 58, 90-96.
16. Ogino,S. et al. (2008) A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J. Natl. Cancer Inst., 100, 1734-1738.
17. Ogino,S. et al. (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J. Mol. Diagn., 7, 413-421.
18. Ogino,S. et al. (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol., 27, 1477-1484.
19. Morikawa,T. et al. (2012) Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int. J. Cancer, 131, 1169-1178.
20. Ogino,S. et al. (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut, 60, 397-411.
21. Vanderweele,T.J. et al. (2010) Odds ratios for mediation analysis for a dichotomous outcome. Am. J. Epidemiol., 172, 1339-1348.
22. Valeri,L. et al. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol. Methods, in press.
23. Knol,M.J. et al. (2007) Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int. J. Epidemiol., 36, 1111-1118.
24. Benjamini,Y. et al. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B. Stat. Methodol., 57, 289-300.
25. Passarelli,M.N. et al. (2011) Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of postmenopausal women. Genes. Chromosomes Cancer, 50, 875-886.
26. Ogino,S. et al. (2010) Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J. Natl. Cancer Inst., 102, 365-367.
27. Ahlquist,T. et al. (2008) Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol. Cancer, 7, 94.
28. Soong,R. et al. (2009) The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br. J. Cancer, 100, 676-679.
29. Subramaniam,M.M. et al. (2009) RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am. J. Gastroenterol., 104, 426-436.
30. Slattery,M.L. et al. (2011) Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer. Cancer, 117, 4175-4183.
31. Ito,K. et al. (2008) RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell, 14, 226-237.
32. Ghazi,S. et al. (2010) Colorectal cancer susceptibility loci in a populationbased study: associations with morphological parameters. Am. J. Pathol., 177, 2688-2693.
33. Piñol,V. et al. (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA, 293, 1986-1994.
34. Abulí,A. et al. (2010) Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology, 139, 788-96, 796.e1.
35. Lubbe,S.J. et al. (2012) Relationship between 16 susceptibility loci and colorectal cancer phenotype in 3146 patients. Carcinogenesis, 33, 108-112.
36. Slattery,M.L. et al. (2010) Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res., 70, 1479-1485.
37. Fleming,Y.M. et al. (2009) TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation. Oncogene, 28, 983-993.
38. Chan,A.T. et al. (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med., 356, 2131-2142.